Effects of liver diseases on drug metabolism

Therapie

Volumn 51, Issue 4, 1996, Pages 384-389

  Paintaud, G ^a   Bechtel, Y ^a   Brientini, M P ^a   Miguet, J P ^a   Bechtel, P R ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Cirrhosis; Cytochrome P450; Hepatitis; Liver diseases; Metabolism

Indexed keywords

CAFFEINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; CYTOKINE; ERYTHROMYCIN; LIDOCAINE; PHENAZONE;

CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG CONJUGATION; DRUG ELIMINATION; DRUG METABOLISM; HEPATITIS; HISTOLOGY; HUMAN; LIVER DISEASE; PRIORITY JOURNAL;

CYSTIC FIBROSIS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; LIVER DISEASES;

EID: 0029777543     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988; 15: 396-420.
2. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989; 40: 439-474.
3. Secor JW, Schenker S. Drug metabolism in patients with liver disease. Adv Intern Med 1987; 32: 379-406.
4. Tröger U, Meyer FP. Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation. Clin Pharmacokinet 1995; 28: 287-314.
5. Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J Hepatol 1988; 6: 374-382.
6. Pelkonen O, Breimer DD. Role of environmental factors in the pharmacokinetics of drugs: considerations with respect to animal models, P-450 enzymes, and probe drugs. In: Welling PG, Balant LP, eds. Handbook of experimental pharmacology, Vol. 110. Pharmacokinetics of drugs. Berlin: Springer-Verlag, 1994: 289-332.
7. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973; 14: 569-573.
8. Sherlock S, Dooley J. Diseases of the liver and biliary system. 9th edition. Oxford: Blackwell, 1993.
9. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1987; 316: 521-528.
10. Dickson ER, Grambsch PM, Fleming TR et al. Prognosis in primary biliary cirrhosis: a model for decision making. Hepatology 1989; 10: 1-7.
11. Tygstrup N. Assessment of liver function: principles and practice. J Gastroenterol Hepatol 1990; 5: 468-482.
12. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
13. Schaffner E, Popper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239-242.
14. Homeida M, Roberts CJC, Halliwell M et al. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. Gut 1979; 20: 596-601.
15. George J, Liddle C, Murray M et al. Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 1995; 49: 873-881.
16. Morgan DJ, Smallwood RA. Clinical significance of pharmacokinetic models of hepatic elimination. Clin Pharmacokinet 1990; 18: 61-76.
17. Barré J, Mallat A, Rosenbaum J et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987; 23: 753-757.
18. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22: 541-550.
19. Tucker GT, Jackson PR, Lennard MS, Woods HF. Pharmacokinetic-pharmacogenetic modelling. A basis for the display and detection of polymorphisms in drug metabolism. In: Alván G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Pithan K, eds. COST B1, European Consensus Conference on Pharmacogenetics. Brussels: Commission of the European Communities, 1990.
20. Teunissen MWE, Spoelstra P, Koch CW et al. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1984; 18: 707-715.
21. PA (P-450IA2), the phenacetin-O-demethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogen arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700.
22. Renner E, Wietholtz H, Huguenin P et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4: 38-46.
23. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
24. Catteau A, Bechtel YC, Poisson N et al. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47: 423-430.
25. Masimirembwa CM, Beke M, Hasler JA et al. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 1995; 57: 25-31.
26. Sotaniemi EA, Rautio A, Bäckstrom M et al. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 1995; 39: 71-76.
27. Larrey D, Babany G, Tinel M et al. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. Br J Clin Pharmacol 1989; 28: 297-304.
28. Lanthier PL, Reshef R, Shah RR et al. Oxidation phenotyping in alcoholics with liver diseases of varying severity. Alcohol Clin Exp Res 1984; 8: 435-441.
29. Joanne C, Paintaud G, Bresson-Hadni S et al. Is debrisoquine hydroxylation modified during acute viral hepatitis? Fundam Clin Pharmacol 1994; 8: 76-79.
30. Joanne C. Effet de la pathologie sur l'expression du phénotype d'oxydation de la débrisoquine chez l'homme. Etude à partir de 1000 observations. Thesis, University of Franche-Comté, 1994.
31. Paintaud G, Bechtel Y, Joanne C et al. Debrisoquine metabolism and CYP2D6 phenotype after liver transplantation. Fundam Clin Pharmacol 1993; 7: 375.
32. Bendriss A, Bechtel Y, Paintaud G et al. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients. Ther Drug Monit 1995; 17: 113-119.
33. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
34. Reichen J. MEGX test in hepatology: the long-sought ultimate quantitative liver function test? J Hepatol 1993; 19: 4-7.
35. Sallie RW, Tredger JM, Williams R. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX). Biopharm Drug Dispos 1992; 13: 555-558.
36. Lown K, Kolars J, Turgeon K et al. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992; 51: 229-238.
37. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology 1991; 13: 786-795.
38. Sonne J. Factors and conditions affecting the glucuronidation of oxazepam. Pharmacol Toxicol 1993; 73: Suppl. 1.
39. Williams RL, Upton RA, Cello JP et al. Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol 1984; 27: 291-296.
40. Tephly TR, Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. TIPS 1990; 11: 276-279.
41. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993; 27: 74-79.
42. O'Sullivan TA, Wang JP, Unadkat JD et al. Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1993; 54: 323-328.
43. Hamelin BA, Xu K, Vallé F et al. Caffeine metabolism in cystic fibrosis: enhanced xanthine oxydase activity. Clin Pharmacol Ther 1994; 56: 521-529.
44. Cribb AE, Tsui B, Isbrucker R et al. Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients. Br J Clin Pharmacol 1995; 39: 85-89.
45. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253-278.
46. Shedlofsky SI, Israel BC, McClain CJ et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94: 2209-2214.
47. 1) in the hamster. Biochem Pharmacol 1989; 38: 439-447.
48. Vermeulen AM, Belpaire FM, De Smet F, Bogaert MG. Influence of human recombinant interleukin-1β on the enantioselective disposition of propanolol in rats. Biochem Pharmacol 1993; 45: 1-6.
49. Williams JF, Bement WJ, Sinclair JF, Sinclair PR. Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes. Biochem Biophys Res Commun 1991; 178: 1049-1055.
50. Chen YL, Le Vraux V, Leneveu A et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-660.
51. Naranjo CA, Busto U, Janecek E et al. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease. Br J Clin Pharmacol 1983; 15: 451-458.